Lysine demethylase 6 (KDM6): A promising therapeutic target in autoimmune disorders and cancer
- PMID: 40516332
- DOI: 10.1016/j.biopha.2025.118254
Lysine demethylase 6 (KDM6): A promising therapeutic target in autoimmune disorders and cancer
Abstract
Epigenetic dynamics, which influence gene expressions independent of DNA sequence alterations, play a pivotal role in regulating chromatin structure and transcription. Among these modifications, the dynamic methylation and demethylation of histone 3 lysine 27 (H3K27me2/3) by the Lysine Demethylase 6 (KDM6) subfamily are pivotal regulators of both physiological and pathological processes. In immune cells, KDM6A and KDM6B fine-tune the transcription of pro- and anti-inflammatory genes, influencing differentiation, polarization, and activation states in monocytes, macrophages, dendritic cells, T helper cells, and other key immune subsets. Dysregulated KDM6 activity underlies aberrant cytokine production, Th17 cell expansion, and imbalances in tissue repair responses, thus contributing to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. Concurrently, KDM6A and KDM6B can act as either tumor suppressors or oncogenes in a context-dependent manner, mediating cellular proliferation, DNA damage repair pathways, and immune evasion in cancers ranging from hematologic malignancies to solid tumors of the bladder, breast, and brain. Recent efforts to exploit this duality include developing small-molecule inhibitors, notably GSK-J4, which block KDM6 demethylase activity and show promising therapeutic effects in models of chronic inflammation and cancer. Nonetheless, challenges such as incomplete target specificity, the interplay with other epigenetic mechanisms, and variations in tumor microenvironment emphasize the complexity of translating these findings into clinical practice. This review highlights the structural features, regulatory mechanisms, and disease associations of KDM6 demethylases, positioning them as compelling biomarkers and therapeutic targets at the intersection of autoimmunity and cancer.
Keywords: Autoimmune disease; Cancer; Epigenetic modification; Histone lysine demethylase.
Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest I hereby declare that I have no conflicts of interest to disclose in relation to the manuscript entitled " Lysine Demethylase 6: A Promising Therapeutic Target in Autoimmunity and Cancer".
Similar articles
-
Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B.Cell Commun Signal. 2024 Oct 31;22(1):528. doi: 10.1186/s12964-024-01912-3. Cell Commun Signal. 2024. PMID: 39482699 Free PMC article.
-
Epigenetic regulation of TIMP-3 expression in human macrophages via physiological and pharmacological modification of histone3 lysine27 (H3K27).Mol Biol Rep. 2025 Aug 1;52(1):775. doi: 10.1007/s11033-025-10872-x. Mol Biol Rep. 2025. PMID: 40748417
-
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach.Clin Epigenetics. 2025 Jun 19;17(1):105. doi: 10.1186/s13148-025-01913-0. Clin Epigenetics. 2025. PMID: 40537846 Free PMC article.
-
Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges.J Clin Invest. 2024 Oct 15;134(20):e183391. doi: 10.1172/JCI183391. J Clin Invest. 2024. PMID: 39403928 Free PMC article. Review.
-
Demystifying the Role of Histone Demethylases in Colorectal Cancer: Mechanisms and Therapeutic Opportunities.Curr Issues Mol Biol. 2025 Apr 9;47(4):267. doi: 10.3390/cimb47040267. Curr Issues Mol Biol. 2025. PMID: 40699666 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical